Όλο το DSpace

Πλοήγηση ανά Θέμα "familial hypercholesterolemia"

Αποτελέσματα 1-2 από 2

    • Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 

      Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)
      Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...

    • Regulatory delays in a multinational clinical stroke trial 

      de Jonge J.C., Reinink H., Colam B., Alpers I., Ciccone A., Csiba L., Kõrv J., Kurkowska-Jastrzebska I., Macleod M.R., Ntaios G., Thomalla G., Bath P.M., van der Worp H.B. (2021)
      Introduction: The initiation and conduct of randomised clinical trials are complicated by multiple barriers, including delays in obtaining regulatory approvals. Quantitative data on the extent of the delays due to national ...